COVID-19 UPDATE: We are open! Our team is working and offering consultations via phone, e-mail, and video conferencing.

Free Consultations Available


Recent Posts in Prescription Drugs Category

  • OxyContin Heiress Purchases $3M Mansion

    While families around the country reel from the effects of the opioid crisis, the Sackler family, who invented and made much of its fortune off OxyContin, continues to thrive. Just this month, OxyContin Heiress Madeleine Sackler paid $3,235,000 in cash for a luxurious Mediterranean villa-style home in a popular Los Angeles neighborhood. Meanwhile, another member of the Sackler family profited from ...
    Continue Reading
  • Between a Rock and a Hard Place

    Type II diabetics are now being told that the drug Actos, manufactured by Takeda Pharmaceutical Co., may be linked to a higher risk of bladder cancer. The information comes from preliminary results of a 10-year study sponsored by Takeda following over 193,000 Actos users. This unsettling news comes on the heels of study results by the manufacturer of Avandia, an Actos competitor, that there may be ...
    Continue Reading
  • Avandia Health Concerns Crosses the Pond

    We previously wrote concerning increased heart attack and heart failure risks to those taking the prescription drug Avandia (Rosiglitazone). The drug, manufactured by GlaxoSmithKline (GSK), is prescribed to Type II (non-insulin dependent) diabetics. The FDA has taken under advisement the issue of whether or not to increase warnings and precautions of taking the drug or to completely remove the ...
    Continue Reading
  • Update on the Avandia/Actos Saga

    A Colorado Business Litigation Lawyer Blog posted August 18, 2010 reported on the SmithKline study that clearly showed that Avandia (a diabetes drug) had a significantly higher heart attack and death risk than its competitor drug Actos. Along comes a new study funded by WellPoint, Inc. that claims to show that the increased risk of heart problems linked to either drug is exactly the same at 4%. ...
    Continue Reading
  • An Introduction to Business Ethics

    Here’s an article I wrote back in July. Before a decision was made whether or not to post it, the FDA advisory panel (a group of scientists) recommended by a split vote that Avandia be left on the market, pending a decision by the head of the FDA, which should be forthcoming. When her decision is made, I will write a follow-up. How often have we read or watched media stories about greedy trial ...
    Continue Reading
Page 1 of 1